Browse by author
Lookup NU author(s): Professor Nicola PaveseORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2022 International Society for Neurochemistry. Converging translational and clinical research strongly indicates that altered immune and inflammatory homeostasis (neuroinflammation) plays a critical pathophysiological role in Alzheimer's disease (AD), across the clinical continuum. A dualistic role of neuroinflammation may account for a complex biological phenomenon, representing a potential pharmacological target. Emerging blood-based pathophysiological biomarkers, such as cytokines (Cyt) and interleukins (ILs), have been studied as indicators of neuroinflammation in AD. However, inconsistent results have been reported probably due to a lack of standardization of assays with methodological and analytical differences. We used machine-learning and a cross-validation-based statical workflow to explore and analyze the potential impact of key biological factors, such as age, sex, and apolipoprotein-E (APOE) genotype (the major genetic risk factor for late-onset AD) on Cyt. A set of Cyt was selected based on previous literature, and we investigated any potential association in a pooled cohort of cognitively healthy, mild cognitive impairment (MCI), and AD-like dementia patients. We also performed explorative analyses to extrapolate preliminary clinical insights. We found a robust sex effect on IL12 and an APOE-related difference in IL10, with the latter being also related to the presence of advanced cognitive decline. IL1β was the variable most significantly associated with MCI-to-dementia conversion over a 2.5 year-clinical follow-up. Although preliminary, our data support further clinical research to understand whether plasma Cyt may represent reliable and noninvasive tools serving the investigation of neuroimmune and inflammatory dynamics in AD and to foster biomarker-guided pathway-based therapeutic approaches, within the precision medicine development framework. (Figure presented.).
Author(s): Galgani A, Vergallo A, Campese N, Lombardo F, Pavese N, Petrozzi L, LoGerfo A, Franzini M, Cecchetti D, Puglisi-Allegra S, Busceti CL, Siciliano G, Tognoni G, Baldacci F, Lista S, Hampel H, Fornai F, Giorgi FS
Publication type: Article
Publication status: Published
Journal: Journal of Neurochemistry
Year: 2022
Volume: 163
Issue: 1
Pages: 40-52
Print publication date: 01/10/2022
Online publication date: 11/08/2022
Acceptance date: 06/08/2022
ISSN (print): 0022-3042
ISSN (electronic): 1471-4159
Publisher: John Wiley and Sons Inc.
URL: https://doi.org/10.1111/jnc.15686
DOI: 10.1111/jnc.15686
PubMed id: 35950445
Altmetrics provided by Altmetric
